A Multi-Center, Open-Label, Single-Arm, Phase 2 Study of ASONEP (Sonepcizumab/LT1009) Administered as a Single Agent to Subjects With Refractory Renal Cell Carcinoma

Trial Profile

A Multi-Center, Open-Label, Single-Arm, Phase 2 Study of ASONEP (Sonepcizumab/LT1009) Administered as a Single Agent to Subjects With Refractory Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Sonepcizumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Lpath
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Efficacy and safety results (n=40) published in the Cancer.
    • 19 Jan 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top